Press release
Relapsing Refractory Multiple Myeloma Pipeline Outlook Report 2025: Key 55+ Companies and Breakthrough Therapies Shaping the Future Landscape
Stay ahead with the latest insights! Download DelveInsight's comprehensive Relapsing Refractory Multiple Myeloma Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Relapsing Refractory Multiple Myeloma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Relapsing Refractory Multiple Myeloma Pipeline Report
* In August 2025, Bristol-Myers Squibb announced a study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
* In August 2025, Celgene announced a study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
* In August 2025, Gracell Biotechnologies (Shanghai) Co., Ltd . announced a study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.
* DelveInsight's Relapsing Refractory Multiple Myeloma pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Relapsing Refractory Multiple Myeloma treatment.
* The leading Relapsing Refractory Multiple Myeloma Companies such as Bristol-Myers Squibb, I-MAB Biopharma, Pfizer, Arcellx, Gilead Sciences, Novartis, Array Biopharma, Hrain Biotechnology Co., Ltd., Cartesian Therapeutics, Xencor, Takeda, Sorrento Therapeutics, Heidelberg Pharma AG, Ichnos Sciences, Allogene Therapeutics, Harpoon Therapeutics, Cellectis, Poseida Therapeutics, Regeneron Pharmaceuticals, ONK Therapeutics, TeneoOne, iTeos Therapeutics, Oricell Therapeutics, Anaveon AG, Luminary Therapeutics, Seagen Inc., Trillium Therapeutics Inc., Virtuoso BINco, Inc . and others.
* Promising Relapsing Refractory Multiple Myeloma Pipeline Therapies such as Elranatamab, Venetoclax, Daratumumab, Carfilzomib, Pomalidomide, Bortezomib, LBH589 (panobinostat), ATG-010 and others.
Discover how the Relapsing Refractory Multiple Myeloma treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Relapsing Refractory Multiple Myeloma Clinical Trials and Studies [https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Relapsing Refractory Multiple Myeloma Emerging Drugs Profile
* Mezigdomide: Bristol-Myers Squibb
Cereblon E3 ligase modulators (CELMoD) are a class of oral immunomodulatory therapeutics that are designed to stimulate the immune system and directly kill cancer cells by inducing the degradation of tumor-promoting proteins. Bristol Myers Squibb is investigating two novel CELMoD agents, mezigdomide and iberdomide, for multiple myeloma that were intentionally designed to improve upon the demonstrated efficacy of the IMiD Registered agents, along with manageable tolerability, ease of administration, and the potential to improve patient outcomes. These agents co-opt cereblon to induce degradation of target proteins Ikaros and Aiolos, which inhibits tumor cell proliferation, promote tumor cell death, and induce immune-stimulatory effects. Mezigdomide induces maximal degradation of Ikaros and Aiolos, leading to increased apoptosis in myeloma cells. Based on Phase I/II interim results, mezigdomide, in combination with weekly DEX (40 mg; 20 mg if >75 years of age), showed promising efficacy in a highly refractory patient population. Mezigdomide is currently being investigated in Phase III stage of development for the treatment of Relapsed or Refractory Multiple Myeloma.
* Iopofosine: Cellectar Biosciences, Inc.
Iopofosine is a small-molecule Phospholipid Drug Conjugate Trademark designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells. We believe this profile differentiates iopofosine from many traditional on-market treatments. Iopofosine is currently being evaluated in the CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom's macroglobulinemia (WM), a Phase 2b study in r/r multiple myeloma (MM) patients and the CLOVER-2 Phase 1 study for a variety of pediatric cancers. The U.S. Food and Drug Administration granted iopofosine Fast Track Designation for WM patients having received two or more prior treatment regimens, as well as r/r MM and r/r diffuse large B-cell lymphoma (DLBCL). Orphan Drug Designations (ODDs) have been granted for WM, MM, neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma and osteosarcoma. Iopofosine was also granted Rare Pediatric Disease Designation (RPDD) for the treatment of neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma and osteosarcoma. The European Commission granted an ODDs for r/r MM and WM.
* ORIC-533: ORIC Pharmaceuticals
ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Relapsed or Refractory Multiple Myeloma.
The Relapsing Refractory Multiple Myeloma Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Relapsing Refractory Multiple Myeloma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsing Refractory Multiple Myeloma Treatment.
* Relapsing Refractory Multiple Myeloma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Relapsing Refractory Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsing Refractory Multiple Myeloma market.
Get a detailed analysis of the latest innovations in the Relapsing Refractory Multiple Myeloma pipeline. Explore DelveInsight's expert-driven report today! @ Relapsing Refractory Multiple Myeloma Unmet Needs [https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Relapsing Refractory Multiple Myeloma Companies
Bristol-Myers Squibb, I-MAB Biopharma, Pfizer, Arcellx, Gilead Sciences, Novartis, Array Biopharma, Hrain Biotechnology Co., Ltd., Cartesian Therapeutics, Xencor, Takeda, Sorrento Therapeutics, Heidelberg Pharma AG, Ichnos Sciences, Allogene Therapeutics, Harpoon Therapeutics, Cellectis, Poseida Therapeutics, Regeneron Pharmaceuticals, ONK Therapeutics, TeneoOne, iTeos Therapeutics, Oricell Therapeutics, Anaveon AG, Luminary Therapeutics, Seagen Inc., Trillium Therapeutics Inc., Virtuoso BINco, Inc . and others.
Relapsing Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Relapsing Refractory Multiple Myeloma Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Download DelveInsight's latest report to gain strategic insights into upcoming Relapsing Refractory Multiple Myeloma Therapies and key Developments @ Relapsing Refractory Multiple Myeloma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Relapsing Refractory Multiple Myeloma Pipeline Report
* Coverage- Global
* Relapsing Refractory Multiple Myeloma Companies- Bristol-Myers Squibb, I-MAB Biopharma, Pfizer, Arcellx, Gilead Sciences, Novartis, Array Biopharma, Hrain Biotechnology Co., Ltd., Cartesian Therapeutics, Xencor, Takeda, Sorrento Therapeutics, Heidelberg Pharma AG, Ichnos Sciences, Allogene Therapeutics, Harpoon Therapeutics, Cellectis, Poseida Therapeutics, Regeneron Pharmaceuticals, ONK Therapeutics, TeneoOne, iTeos Therapeutics, Oricell Therapeutics, Anaveon AG, Luminary Therapeutics, Seagen Inc., Trillium Therapeutics Inc., Virtuoso BINco, Inc . and others.
* Relapsing Refractory Multiple Myeloma Pipeline Therapies- Elranatamab, Venetoclax, Daratumumab, Carfilzomib, Pomalidomide, Bortezomib, LBH589 (panobinostat), ATG-010 and others.
* Relapsing Refractory Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Relapsing Refractory Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Relapsing Refractory Multiple Myeloma drug development? Find out in DelveInsight's exclusive Pipeline Report-access it now! @ Relapsing Refractory Multiple Myeloma Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Relapsing Refractory Multiple Myeloma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Relapsing Refractory Multiple Myeloma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Mezigdomide: Bristol-Myers Squibb
* Mid Stage Products (Phase II)
* Iopofosine: Cellectar Biosciences, Inc.
* Early Stage Products (Phase I)
* ORIC-533: ORIC Pharmaceuticals
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Relapsing Refractory Multiple Myeloma Key Companies
* Relapsing Refractory Multiple Myeloma Key Products
* Relapsing Refractory Multiple Myeloma- Unmet Needs
* Relapsing Refractory Multiple Myeloma- Market Drivers and Barriers
* Relapsing Refractory Multiple Myeloma- Future Perspectives and Conclusion
* Relapsing Refractory Multiple Myeloma Analyst Views
* Relapsing Refractory Multiple Myeloma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=relapsing-refractory-multiple-myeloma-pipeline-outlook-report-2025-key-55-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/relapsing-refractory-multiple-myeloma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Relapsing Refractory Multiple Myeloma Pipeline Outlook Report 2025: Key 55+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4134148 • Views: …
More Releases from ABNewswire
Housebell Launches Singapore's First Bilingual AI-Powered Property Platform
Image: https://www.abnewswire.com/upload/2025/08/dd52626b3d8f2924cbee5bc5d45f6779.jpg
Singapore - August 25th, 2025 - Singapore's property market, long dominated by a few major players, is entering a new era of disruption with the launch of Housebell [https://www.housebell.com/], the nation's first bilingual AI-powered real estate platform. Featuring over 10,000 verified property listings, intelligent matchmaking, and immersive VR property tours, Housebell aims to make property searches more transparent, efficient, and inclusive for both local and overseas users.
Breaking the Monopoly,…
Thrivepop Drives Business Growth Through Innovative Marketing Strategies
Nowadays, every company has to have a loud voice to get heard. Marketing isn't merely putting up advertisements or posting content. It's about reaching out to people, gaining their trust, and establishing a brand that people recall. Thrivepop [https://thrivepop.com/] gets this requirement and collaborates with companies to make them thrive through innovative and result-oriented marketing.
Simplifying and Making Marketing Effective
It is hard for most businesses to keep pace with the high…
Haute Retreats Unveils Exclusive Caribbean Vacation Guide for Families Seeking W …
When the cold winds of winter sweep across North America and Europe, families often start searching for a warm escape where sunshine, turquoise waters, and laid-back island charm create the perfect vacation backdrop. The Caribbean, with its diverse islands and luxury accommodations, stands out as a premier choice for winter holidays. Families looking for comfort, privacy, and personalized experiences often turn to Luxury Villas in the Caribbean with Haute Retreats…
Oil Steel Pipe: Materials, Properties, and Common Sizes - ROYAL GROUP
In the vast oil industry, Oil steel pipes play a vital role, serving as a key carrier in the delivery of oil and natural gas from underground extraction to end users. From drilling operations in oil and gas fields to long-distance pipeline transportation, various types of Oil [https://www.royalsteelgroup.com/api-5l-gr-b-astm-a53-a106-carbon-seamless-line-pipe-product/]steel pipes [https://www.royalsteelgroup.com/api-5l-gr-b-astm-a53-a106-carbon-seamless-line-pipe-product/], with their unique materials and properties, ensure the safe and efficient operation of the entire industry chain. This article will…
More Releases for Multiple
Mango AI's Multiple Face Swap Video Tool Changes Multiple Faces Instantly
In today's digital world, creating eye-catching and unique content is essential for standing out. The ability to swap multiple faces in a single video opens up creative possibilities, whether for personalized content, comedy or parody videos, or engaging social media posts. Mango AI, developed by Mango Animate, is excited to announce the launch of its advanced multiple face swap video (https://mangoanimate.com/ai/multiple-face-swap-video) tool, which is designed to simplify the creation of…
Multiple Sclerosis Drugs Market
Global Multiple Sclerosis Drugs Market Size research report offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market.
Get a Sample Copy of the Report at - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100386
Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as progressive brain and spinal cord atrophy and neuroaxonal…
Massive Multiple Input Multiple Output (MIMO) Market May Set New Growth Story
A Latest intelligence report published by MR Forecast with title "Global Massive Multiple Input Multiple Output (MIMO) Market Outlook to 2032. A detailed study accumulated to offer Latest insights about acute features of the Massive Multiple Input Multiple Output (MIMO) market. This report provides a detailed overview of key factors in the Global Massive Multiple Input Multiple Output (MIMO) Market and factors such as driver, restraint, past and current trends,…
Multiple Sclerosis Drugs Market - Progressing Towards a Cure: Advancing Multiple …
Newark, New Castle, USA: The "Multiple Sclerosis Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Multiple Sclerosis Drugs Market: https://www.growthplusreports.com/report/multiple-sclerosis-drugs-market/7983
This latest report researches the industry structure,…
Multiple Sclerosis Drugs Market - Empowering Resilience, Embracing Possibilities …
Newark, New Castle, USA - new report, titled Multiple Sclerosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Multiple Sclerosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Multiple Sclerosis Drugs market. The report offers an overview of…
Massive MIMO (Multiple-input multiple-output) Market 2022-2028 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Massive MIMO (Multiple-input multiple-output) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Massive MIMO (Multiple-input multiple-output) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Massive MIMO (Multiple-input multiple-output)…
